|
GTHX
|
G1 Therapeutics, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
GRTS
|
Gritstone Oncology, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
GLUE
|
Monte Rosa Therapeutics, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
GBIO
|
Generation Bio Co.
|
0.02%
|
US
|
NASDAQ
|
|
DBVT
|
DBV Technologies S.A.
|
0.02%
|
US
|
NASDAQ
|
|
CMPS
|
COMPASS Pathways Plc
|
0.02%
|
US
|
NASDAQ
|
|
CINC
|
CinCor Pharma, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
BMEA
|
Biomea Fusion, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
ATNM
|
Actinium Pharmaceuticals, Inc.
|
0.02%
|
US
|
AMEX
|
|
ATAI
|
ATAI Life Sciences N.V.
|
0.02%
|
US
|
NASDAQ
|
|
ANNX
|
Annexon, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
ALXO
|
ALX Oncology Holdings Inc.
|
0.02%
|
US
|
NASDAQ
|
|
ALVR
|
AlloVir, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
ALPN
|
Alpine Immune Sciences, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
AKYA
|
Akoya BioSciences, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
ADCT
|
ADC Therapeutics SA
|
0.02%
|
US
|
NYSE
|
|
ADAP
|
Adaptimmune Therapeutics plc
|
0.02%
|
US
|
NASDAQ
|
|
ACET
|
Adicet Bio, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
NGM
|
NGM Biopharmaceuticals, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
URGN
|
UroGen Pharma Ltd.
|
0.01%
|
US
|
NASDAQ
|